Mastodon

Cholebil (Capsules) Instructions for Use

Marketing Authorization Holder

Europlant Phytopharm, Sp. z o.o. (Poland)

ATC Code

A05AX (Other drugs for the treatment of biliary tract diseases)

Active Substance

Cynara (BAN)

Dosage Form

Bottle OTC Icon Cholebil Capsules 400 mg

Dosage Form, Packaging, and Composition

Capsules are hard gelatin capsules No. 0, the upper part (cap) and the lower part (body) are matte, brown in color. The contents of the capsule are a powder ranging from yellowish-brown to brown in color with a characteristic odor.

1 caps.
Artichoke leaf extract 400 mg

Excipients: talc, magnesium stearate, colloidal silicon dioxide, corn starch, lactose monohydrate.

Capsule shell composition: gelatin, purified water, sodium lauryl sulfate, titanium dioxide E171, red iron oxide E172, black iron oxide E172, yellow iron oxide E172.

10 pcs. – blisters made of PVC/PVDC/aluminum foil (2) – cardboard packs.

Clinical-Pharmacological Group

Herbal preparation with hepatoprotective and choleretic action

Pharmacotherapeutic Group

Choleretic agent of plant origin

Pharmacological Action

It has a choleretic and hepatoprotective effect, due to the content of a complex of biologically active substances from artichoke leaf extract – the phenolic compound cynarin in combination with phenolic acids (chlorogenic acid, etc.).

The drug stimulates the formation and outflow of bile, intestinal peristalsis, helps improve digestion processes and reduce the cholesterol content in the blood.

Indications

  • As part of complex therapy for dyspeptic syndrome in chronic non-erosive gastritis, duodenitis;
  • Steatosis;
  • Chronic hepatitis of various etiologies with a mild course;
  • Chronic non-calculous cholecystitis, biliary dyskinesia;
  • Postcholecystectomy syndrome;
  • Chronic pancreatitis;
  • Chronic colitis.

ICD codes

ICD-10 code Indication
B18 Chronic viral hepatitis
K29 Gastritis and duodenitis
K30 Functional dyspepsia (digestive disorder)
K52 Other noninfectious gastroenteritis and colitis
K73 Chronic hepatitis, not elsewhere classified
K76.0 Fatty (change of) liver, not elsewhere classified
K81.1 Chronic cholecystitis
K82.8 Other specified diseases of gallbladder and cystic duct (including dyskinesia)
K86.1 Other chronic pancreatitis
K91.5 Postcholecystectomy syndrome
ICD-11 code Indication
1E51.Z Chronic viral hepatitis, unspecified
DA42.81 Radiation gastritis
DA42.8Z Gastritis due to external causes, unspecified
DA42.Z Gastritis, unspecified
DA51.53 Radiation duodenitis
DA51.5Z Duodenitis due to external causes, unspecified
DA51.Z Duodenitis, unspecified
DA7Z Diseases of stomach or duodenum, unspecified
DB33.2Z Allergic or alimentary colitis, unspecified
DB33.4Y Other specified colitis or proctitis caused by external agents
DB33.4Z Colitis or proctitis caused by external agents, unspecified
DB92.0 Non-alcoholic fatty liver disease without steatohepatitis
DB92.Y Other specified non-alcoholic fatty liver disease
DB92.Z Non-alcoholic fatty liver disease, unspecified
DB97.2 Chronic hepatitis, not elsewhere classified
DC12.1 Chronic cholecystitis
DC14.1 Postcholecystectomy syndrome
DC1Z Diseases of gallbladder and biliary tract, unspecified
DC32.0 Calcific pancreatitis
DC32.1 Paraduodenal pancreatitis
DC32.2 Hereditary chronic pancreatitis
DC32.4 Chronic idiopathic pancreatitis
DC32.5 Tropical pancreatitis
DC32.Z Chronic pancreatitis, unspecified
DC33 Autoimmune pancreatitis
DD90.0 Globus sensation
DD90.1 Functional dysphagia
DD90.3 Functional dyspepsia
DD90.Z Functional disorders of esophagus or gastroduodenal system, unspecified
DD94 Functional disorder of the gallbladder
DE2Z Diseases of the digestive system, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Take this medication orally.

Swallow the capsule whole with a sufficient amount of liquid.

Take the capsule with meals to improve tolerance and absorption.

The standard adult dose is 1 capsule taken 1 to 2 times per day.

Adhere to the twice-daily regimen if prescribed for more pronounced symptoms.

The typical course of treatment is 3 to 4 weeks.

Continue treatment for the full prescribed duration unless otherwise directed by a physician.

Do not exceed the recommended daily dose of 2 capsules (800 mg).

If no clinical improvement is observed after one week of use, consult a physician for re-evaluation.

Adverse Reactions

Allergic reactions, pain in the epigastric region, diarrhea, nausea, heartburn are possible.

Contraindications

  • Hypersensitivity to the drug;
  • Cholelithiasis;
  • Obstruction of the biliary tract;
  • Severe forms of hepatic insufficiency;
  • Acute diseases of the liver, kidneys, biliary and urinary tracts;
  • Pregnancy, lactation period;
  • Children under 18 years of age.

Use in Pregnancy and Lactation

Contraindicated during pregnancy and lactation.

Use in Hepatic Impairment

Contraindicated in severe forms of hepatic insufficiency; acute liver diseases.

Use in Renal Impairment

Contraindicated in acute kidney diseases.

Pediatric Use

Contraindicated in children and adolescents under 18 years of age.

Special Precautions

If no improvement in condition is observed after 7 days of taking the drug, a doctor should be consulted.

Due to the presence of lactose in the composition, it is not recommended for patients with lactose intolerance, lactase deficiency, or glucose-galactose malabsorption.

Effect on ability to drive vehicles or operate machinery

The drug does not affect psychophysical condition, does not cause drowsiness, and does not affect the ability to drive vehicles or operate machinery.

Overdose

Overdose may lead to an increase in the manifestation of the drug’s side effects. Treatment is symptomatic.

Drug Interactions

Concomitant use may weaken the effect of coumarin anticoagulants (phenprocoumon, warfarin), which requires dose adjustment and consultation with the attending physician.

Storage Conditions

Store the drug in a place inaccessible to children at a temperature not exceeding 25°C (77°F).

Shelf Life

Shelf life – 2 years 6 months. Do not use after the expiration date.

Dispensing Status

The drug is approved for use as an over-the-counter product.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS